B. Metzler seel. Sohn & Co. Holding AG Acquires Shares of 52,667 Amgen Inc. (NASDAQ:AMGN)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 52,667 shares of the medical research company's stock, valued at approximately $16,969,000.

A number of other hedge funds have also recently made changes to their positions in the business. Capital International Investors increased its stake in shares of Amgen by 547.8% in the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after buying an additional 5,923,915 shares during the period. Pathway Financial Advisers LLC grew its position in shares of Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after buying an additional 4,446,757 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Amgen by 6.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,701,631 shares of the medical research company's stock worth $844,137,000 after buying an additional 162,223 shares during the period. International Assets Investment Management LLC grew its position in shares of Amgen by 6,812.4% in the 3rd quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after buying an additional 2,486,882 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Amgen by 137.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company's stock worth $676,984,000 after buying an additional 1,377,007 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Amgen stock traded up $1.19 during midday trading on Tuesday, hitting $279.95. The stock had a trading volume of 3,210,343 shares, compared to its average volume of 2,459,217. The firm's fifty day moving average is $319.90 and its two-hundred day moving average is $318.65. The company has a market capitalization of $150.48 billion, a PE ratio of 35.69, a P/E/G ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 52-week low of $260.52 and a 52-week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.96 EPS. On average, research analysts forecast that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen's dividend payout ratio is 115.24%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AMGN shares. Oppenheimer reaffirmed an "outperform" rating and issued a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. TD Cowen upped their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Truist Financial cut shares of Amgen from a "buy" rating to a "hold" rating and upped their price target for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Barclays upped their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $333.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.